Prognostic Impact of Prephase Treatment Prior to First-Line Treatment in DLBCL: A Population-Based Registry Study

Table 2

Grade III-IV toxicities after the first-line regimens of diffuse large B-cell lymphoma.

	All patients (N = 340)	Before propensity score matching			After propensity score matching
		With prephase (N = 126)	Without prephase (N = 214)		With prephase (N = 97)	Without prephase (N = 97)
All toxicities	92 (27%)	40 (32%)	52 (24%)	0.14	25 (26%)	27 (28%)	0.75
Febrile neutropenia	23 (7%)	15 (12%)	8 (4%)	0.004	9 (9%)	5 (5%)	0.27
Neutropenia	74 (22%)	34 (27%)	40 (19%)	0.07	22 (23%)	20 (21%)	0.73
Anemia	13 (4%)	8 (6%)	5 (2%)	0.08	1 (1%)	1 (1%)	1.00
Thrombocytopenia	10 (3%)	5 (4%)	5 (2%)	0.51	4 (4%)	2 (2%)	0.68
Infection	28 (8%)	19 (15%)	9 (4%)	0.0004	11 (11%)	6 (6%)	0.20
Cardiac toxicity	4 (1%)	2 (2%)	2 (1%)	0.63	2 (2%)	2 (2%)	1.00
Neurologic toxicity	2 (1%)	1 (1%)	1 (1%)	1.00	1 (1%)	0	1.00